Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Eunhee Kim, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE-087 study of pembrolizumab in 210 patients, based on HL progression after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV; cohort 1); salvage chemotherapy and BV, with ineligibility for SCT owing to chemorefractory disease (cohort 2); and progression after SCT without BV (cohort 3). With a median follow-up of 27.6 months, the objective response rate (ORR) by blinded independent central review was 71.9% (95% CI, 65.3-77.9), the complete response rate (CRR) was 27.6%, and the partial response (PR) rate was 44.3%. Median duration of response was 16.5 months (range, 0.01 to 27.01 [1, no progressive disease at last assessment]) in all patients, 22.1 months in cohort 1, 11.1 months in cohort 2, and 24.4 months in cohort 3. Median progression-free survival was not reached in all patients with CR: 13.8 months (95% CI, 12.0-22.1) for patients with PR and 10.9 months (95% CI, 5.6-11.1) for patients with stable disease. Median overall survival was not reached in all patients or in any cohort. Treatment-related adverse events (TRAEs) of any grade occurred in 153 (72.9%) patients; grades 3 and 4 occurred in 25 (12.0%) patients; none resulted in death. Results confirmed effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL. This trial was registered at www.clinicaltrials.gov as #NCT02453594.

Original languageEnglish
Pages (from-to)1144-1153
Number of pages10
JournalBlood
Volume134
Issue number14
DOIs
Publication statusPublished - 03-10-2019

Fingerprint

Hodgkin Disease
Refractory materials
Salvaging
Chemotherapy
Stem cells
Durability
pembrolizumab
Stem Cell Transplantation
Disease-Free Survival
Safety
Drug Therapy
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Chen, R., Zinzani, P. L., Lee, H. J., Armand, P., Johnson, N. A., Brice, P., ... Moskowitz, C. H. (2019). Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood, 134(14), 1144-1153. https://doi.org/10.1182/blood.2019000324
Chen, Robert ; Zinzani, Pier Luigi ; Lee, Hun Ju ; Armand, Philippe ; Johnson, Nathalie A. ; Brice, Pauline ; Radford, John ; Ribrag, Vincent ; Molin, Daniel ; Vassilakopoulos, Theodoros P. ; Tomita, Akihiro ; von Tresckow, Bastian ; Shipp, Margaret A. ; Lin, Jianxin ; Kim, Eunhee ; Nahar, Akash ; Balakumaran, Arun ; Moskowitz, Craig H. / Pembrolizumab in relapsed or refractory Hodgkin lymphoma : 2-year follow-up of KEYNOTE-087. In: Blood. 2019 ; Vol. 134, No. 14. pp. 1144-1153.
@article{570fe16417b142ff96b9d28c7815d889,
title = "Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087",
abstract = "Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE-087 study of pembrolizumab in 210 patients, based on HL progression after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV; cohort 1); salvage chemotherapy and BV, with ineligibility for SCT owing to chemorefractory disease (cohort 2); and progression after SCT without BV (cohort 3). With a median follow-up of 27.6 months, the objective response rate (ORR) by blinded independent central review was 71.9{\%} (95{\%} CI, 65.3-77.9), the complete response rate (CRR) was 27.6{\%}, and the partial response (PR) rate was 44.3{\%}. Median duration of response was 16.5 months (range, 0.01 to 27.01 [1, no progressive disease at last assessment]) in all patients, 22.1 months in cohort 1, 11.1 months in cohort 2, and 24.4 months in cohort 3. Median progression-free survival was not reached in all patients with CR: 13.8 months (95{\%} CI, 12.0-22.1) for patients with PR and 10.9 months (95{\%} CI, 5.6-11.1) for patients with stable disease. Median overall survival was not reached in all patients or in any cohort. Treatment-related adverse events (TRAEs) of any grade occurred in 153 (72.9{\%}) patients; grades 3 and 4 occurred in 25 (12.0{\%}) patients; none resulted in death. Results confirmed effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL. This trial was registered at www.clinicaltrials.gov as #NCT02453594.",
author = "Robert Chen and Zinzani, {Pier Luigi} and Lee, {Hun Ju} and Philippe Armand and Johnson, {Nathalie A.} and Pauline Brice and John Radford and Vincent Ribrag and Daniel Molin and Vassilakopoulos, {Theodoros P.} and Akihiro Tomita and {von Tresckow}, Bastian and Shipp, {Margaret A.} and Jianxin Lin and Eunhee Kim and Akash Nahar and Arun Balakumaran and Moskowitz, {Craig H.}",
year = "2019",
month = "10",
day = "3",
doi = "10.1182/blood.2019000324",
language = "English",
volume = "134",
pages = "1144--1153",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "14",

}

Chen, R, Zinzani, PL, Lee, HJ, Armand, P, Johnson, NA, Brice, P, Radford, J, Ribrag, V, Molin, D, Vassilakopoulos, TP, Tomita, A, von Tresckow, B, Shipp, MA, Lin, J, Kim, E, Nahar, A, Balakumaran, A & Moskowitz, CH 2019, 'Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087', Blood, vol. 134, no. 14, pp. 1144-1153. https://doi.org/10.1182/blood.2019000324

Pembrolizumab in relapsed or refractory Hodgkin lymphoma : 2-year follow-up of KEYNOTE-087. / Chen, Robert; Zinzani, Pier Luigi; Lee, Hun Ju; Armand, Philippe; Johnson, Nathalie A.; Brice, Pauline; Radford, John; Ribrag, Vincent; Molin, Daniel; Vassilakopoulos, Theodoros P.; Tomita, Akihiro; von Tresckow, Bastian; Shipp, Margaret A.; Lin, Jianxin; Kim, Eunhee; Nahar, Akash; Balakumaran, Arun; Moskowitz, Craig H.

In: Blood, Vol. 134, No. 14, 03.10.2019, p. 1144-1153.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pembrolizumab in relapsed or refractory Hodgkin lymphoma

T2 - 2-year follow-up of KEYNOTE-087

AU - Chen, Robert

AU - Zinzani, Pier Luigi

AU - Lee, Hun Ju

AU - Armand, Philippe

AU - Johnson, Nathalie A.

AU - Brice, Pauline

AU - Radford, John

AU - Ribrag, Vincent

AU - Molin, Daniel

AU - Vassilakopoulos, Theodoros P.

AU - Tomita, Akihiro

AU - von Tresckow, Bastian

AU - Shipp, Margaret A.

AU - Lin, Jianxin

AU - Kim, Eunhee

AU - Nahar, Akash

AU - Balakumaran, Arun

AU - Moskowitz, Craig H.

PY - 2019/10/3

Y1 - 2019/10/3

N2 - Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE-087 study of pembrolizumab in 210 patients, based on HL progression after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV; cohort 1); salvage chemotherapy and BV, with ineligibility for SCT owing to chemorefractory disease (cohort 2); and progression after SCT without BV (cohort 3). With a median follow-up of 27.6 months, the objective response rate (ORR) by blinded independent central review was 71.9% (95% CI, 65.3-77.9), the complete response rate (CRR) was 27.6%, and the partial response (PR) rate was 44.3%. Median duration of response was 16.5 months (range, 0.01 to 27.01 [1, no progressive disease at last assessment]) in all patients, 22.1 months in cohort 1, 11.1 months in cohort 2, and 24.4 months in cohort 3. Median progression-free survival was not reached in all patients with CR: 13.8 months (95% CI, 12.0-22.1) for patients with PR and 10.9 months (95% CI, 5.6-11.1) for patients with stable disease. Median overall survival was not reached in all patients or in any cohort. Treatment-related adverse events (TRAEs) of any grade occurred in 153 (72.9%) patients; grades 3 and 4 occurred in 25 (12.0%) patients; none resulted in death. Results confirmed effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL. This trial was registered at www.clinicaltrials.gov as #NCT02453594.

AB - Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE-087 study of pembrolizumab in 210 patients, based on HL progression after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV; cohort 1); salvage chemotherapy and BV, with ineligibility for SCT owing to chemorefractory disease (cohort 2); and progression after SCT without BV (cohort 3). With a median follow-up of 27.6 months, the objective response rate (ORR) by blinded independent central review was 71.9% (95% CI, 65.3-77.9), the complete response rate (CRR) was 27.6%, and the partial response (PR) rate was 44.3%. Median duration of response was 16.5 months (range, 0.01 to 27.01 [1, no progressive disease at last assessment]) in all patients, 22.1 months in cohort 1, 11.1 months in cohort 2, and 24.4 months in cohort 3. Median progression-free survival was not reached in all patients with CR: 13.8 months (95% CI, 12.0-22.1) for patients with PR and 10.9 months (95% CI, 5.6-11.1) for patients with stable disease. Median overall survival was not reached in all patients or in any cohort. Treatment-related adverse events (TRAEs) of any grade occurred in 153 (72.9%) patients; grades 3 and 4 occurred in 25 (12.0%) patients; none resulted in death. Results confirmed effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL. This trial was registered at www.clinicaltrials.gov as #NCT02453594.

UR - http://www.scopus.com/inward/record.url?scp=85072945199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072945199&partnerID=8YFLogxK

U2 - 10.1182/blood.2019000324

DO - 10.1182/blood.2019000324

M3 - Article

C2 - 31409671

AN - SCOPUS:85072945199

VL - 134

SP - 1144

EP - 1153

JO - Blood

JF - Blood

SN - 0006-4971

IS - 14

ER -

Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019 Oct 3;134(14):1144-1153. https://doi.org/10.1182/blood.2019000324